HSPA9 and melanoma: Of note, this ability of mortalin to modulate the Raf/MEK/ERK pathway was important for B-RafV600E melanoma and K-RasG12V colon carcinoma cells to bypass the cytostatic effects associated with high MEK/ERK activity [12].